SI1603941T1 - Inhibitorji zunajceliäśnega hsp90 - Google Patents

Inhibitorji zunajceliäśnega hsp90

Info

Publication number
SI1603941T1
SI1603941T1 SI200431636T SI200431636T SI1603941T1 SI 1603941 T1 SI1603941 T1 SI 1603941T1 SI 200431636 T SI200431636 T SI 200431636T SI 200431636 T SI200431636 T SI 200431636T SI 1603941 T1 SI1603941 T1 SI 1603941T1
Authority
SI
Slovenia
Prior art keywords
extracellular hsp90
inhibitors
extracellular
hsp90
invasiveness
Prior art date
Application number
SI200431636T
Other languages
English (en)
Inventor
Daniel G Jay
Brenda K Eustace
Takashi Sakurai
Original Assignee
Univ Tufts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tufts filed Critical Univ Tufts
Publication of SI1603941T1 publication Critical patent/SI1603941T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
SI200431636T 2003-03-12 2004-03-09 Inhibitorji zunajceliäśnega hsp90 SI1603941T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45481303P 2003-03-12 2003-03-12
EP03015115A EP1457499A1 (en) 2003-03-12 2003-07-03 Inhibitors of extracellular Hsp90
EP04718644A EP1603941B1 (en) 2003-03-12 2004-03-09 Inhibitors of extracellular hsp90
PCT/EP2004/002422 WO2004081037A1 (en) 2003-03-12 2004-03-09 Inhibitors of extracellular hsp90

Publications (1)

Publication Number Publication Date
SI1603941T1 true SI1603941T1 (sl) 2011-05-31

Family

ID=32772103

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431636T SI1603941T1 (sl) 2003-03-12 2004-03-09 Inhibitorji zunajceliäśnega hsp90

Country Status (13)

Country Link
EP (2) EP1457499A1 (sl)
JP (1) JP4971788B2 (sl)
CN (1) CN1860132A (sl)
AT (1) ATE494302T1 (sl)
CA (1) CA2518944C (sl)
CY (1) CY1111365T1 (sl)
DE (1) DE602004030890D1 (sl)
DK (1) DK1603941T3 (sl)
ES (1) ES2359240T3 (sl)
PL (1) PL1603941T3 (sl)
PT (1) PT1603941E (sl)
SI (1) SI1603941T1 (sl)
WO (1) WO2004081037A1 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
CA2585091C (en) * 2004-11-03 2016-07-19 University Of Kansas Novobiocin analogues as anticancer agents
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2008079914A1 (en) * 2006-12-21 2008-07-03 Novartis Ag Antibody quantitation
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
MX2010008269A (es) 2008-02-01 2011-02-21 Takeda Pharmaceutical Inhibidores de hsp90.
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
KR101713343B1 (ko) * 2008-08-18 2017-03-22 메소블라스트, 아이엔씨. 단일 클론 항체 ｓｔｒｏ-4
CN101942017B (zh) * 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
CN103694332B (zh) * 2009-07-07 2017-07-11 清华大学 一种新的肿瘤标志物
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20140294725A1 (en) * 2011-07-08 2014-10-02 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
EP2776025A1 (en) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN111197057B (zh) * 2018-11-19 2024-04-19 中国科学院分子细胞科学卓越创新中心 调控免疫细胞迁移的组合物和方法
WO2020119728A1 (zh) * 2018-12-12 2020-06-18 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
CN109568311A (zh) * 2018-12-13 2019-04-05 中国人民解放军总医院 坦螺旋霉素在制备抗菌消炎药物中的应用
CN110511277B (zh) * 2019-09-11 2022-07-26 江苏莱森生物科技研究院有限公司 一种抗hsp90单克隆抗体及其应用
CN115109757B (zh) * 2022-05-11 2023-06-02 江南大学 一株分泌新生霉素单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
AU776652B2 (en) * 1999-03-12 2004-09-16 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of inhibiting a chaperone protein
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections

Also Published As

Publication number Publication date
ATE494302T1 (de) 2011-01-15
ES2359240T3 (es) 2011-05-19
JP2007524586A (ja) 2007-08-30
CN1860132A (zh) 2006-11-08
CY1111365T1 (el) 2015-08-05
CA2518944A1 (en) 2004-09-23
JP4971788B2 (ja) 2012-07-11
PL1603941T3 (pl) 2011-06-30
DK1603941T3 (da) 2011-04-26
CA2518944C (en) 2013-07-30
EP1457499A1 (en) 2004-09-15
EP1603941A1 (en) 2005-12-14
EP1603941B1 (en) 2011-01-05
WO2004081037A1 (en) 2004-09-23
PT1603941E (pt) 2011-03-31
DE602004030890D1 (de) 2011-02-17

Similar Documents

Publication Publication Date Title
CY1111365T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΕΞΩΚΥΤΤΑΡΙΚΗΣ Hsp90
IL164599A0 (en) Combination therapy for the treatment of cancer
WO2003080582A3 (de) Fredericamycin-derivate
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
EP1638514A4 (en) USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER
HK1096298A1 (en) Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
IL174577A0 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ZA200500908B (en) Ruthenium anticancer complexes
HUP0500424A3 (en) Combination therapy for the treatment of cancer
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2005023191A3 (en) Rage-related methods and compositions for treating glomerular injury
AU2003242512A8 (en) Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
HK1088214A1 (en) Pmcol for the treatment of prostate cancer
WO2005016958A3 (en) Compounds for treating tumors
UA85187C2 (en) 2-aminobenzoyl derivatives
WO2001047505A3 (de) Verwendung von azolen zur prävention von hautkrebs
AU2003212990A8 (en) Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
WO2003014128A3 (de) Tumorhemmende cerverbindungen
WO2003004631A3 (en) USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS.
WO2006032537A3 (en) Use of epothilones in the treatment of bone metastases and bone tumors or cancers
WO2004002429A3 (en) Methods of inhibiting pin1-associated states using a fredericamycin a compound